[en] The diabetic kidney disease is the most frequent cause of end stage renal disease in Western countries. Its detection is obtained by simultaneously measuring urinary albumin excretion and estimating glomerular filtration rate through serum creatinine dosage. Many type 1 and type 2 diabetic patients can present decreased glomerular filtration rate before the occurrence of increased urinary albumin. While waiting for promising new pharmacological approaches currently evaluated in clinical trials, the best approach to stop the epidemic of diabetic nephropathy remains an early and individual multifactorial approach controlling the glucose level (without inducing hypoglycaemia), blood pressure (using a renin-angiotensin blocker), dyslipidaemia and over-weight.
American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl.):S14-S80.
Maclsaac R, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney diease. Am J Kidney Dis 2014; 63 (Suppl.): S39-S62.
Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy-beyond the RAS. Nat Rev Nephrol 2014; 10:325-46.
Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: A clinical update from kidney disease: Improving global outcomes. Kidney Int 2015; 87:20-30.
Cohen E, Krzesinski JM. Screening, early diagnosis, genetic markers, and predictors of diabetic nephropathy. In: Lerma EV, Batuman V, eds. Diabetes and kidney disease. New-York: Springer, 2014; 79-89.
Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33:1536-43.
de Boer IH, Rue TC, Cleary PA, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011; 171:412-20.
Retnakaran R, Cull CA, Thorne KI, Adlter AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832-39.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-91.
Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19:2784-8.
Rutter MK, Nesto RW. Blood pressure, lipids and glucose in type 2 diabetes: How low should we go ? Re-discovering personalized care. Eur Heart J 2011; 18: 2247-55.
De Boer IH, Sun W, Cleary PA, Lachin JM, for the DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365:2366-76.
Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012; 172: 761-9.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-65.
Holman R, Paul S, Bethel A, Matthews D, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-89.
Perkovic V, Heerspink HL, Chalmers J, et al. for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-72.
Zoungas S, Chalmers J, Neal B, et al. for the ADVANCE-ON Collaborative Group. Follow-up of blood pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392-406.
Perkovic V, Heerspink HL, Chalmers J, et al. for the ADVANCE Collaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517-23.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-59.
Scheen AJ. A review of gliptins for 2014. Expert Opin Pharmacother 2015; 16:43-62.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75:33-59.
Muskiet MHA, Smits MM, Morsink LM, Diamant M. The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes ? Nat Rev Nephrol 2014; 10: 88-103.
Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014; 37:2884-94.
De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: Targeting the renal tubule in diabetes. Am J Kidney Dis 2014; 64:16-24.
Raffaelli M, Sessa L, Mingrone G, Bellantone R. Assessing the obese diabetic patient for bariatric surgery: Which candidate do I choose ? Diabetes, Metab Syndr Obes 2015; 8: 255-62.
Carlsson LM, Romeo S, Jacobson P, et al. The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): A prospective controlled intervention trial. Int J Obes (Lond) 2015; 39:169-75.
Fioretto P, Steffes MW, Sutherland De, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 329: 69-75.
The Task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-357.
Cushman WC, Evans GW, Byington RP, et al. for The ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-85.
Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight bood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-8.
Argawal R, Andersen MJ. Prognosis importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006; 69:1175-80.
Cardoso CR, Leite NC, Muxfeldt Es, Salles GF. Thresh-olds of ambulatory blood pressure associated with chronic complications in type 2 diabetes. Am J Hypertens 2012; 25:82-8.
Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6:319-30.
Charyntan DM, Forman JP. You are what you eat: Dietary salt intake and renin-angiotensin blockade in diabetic nephropathy. Kidney Int 2012; 82 :257-9.
Ruggenenti P, Porrini EL, Gaspari F, et al. for the GFR Study Investigators. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35:2061-8.
Krzesinski JM, Scheen AJ. Y a-t-il encore une place pour la double inhibition du système rénine-angiotensine en 2012 ? Rev Med Suisse 2012; 8:1598-603.
Parving HH, Brenner BM, McMurray JJV, et al. for the ALTITUDE Investigators. Cardiorenal end point in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-13.
Freid L, Emanuele N, Brophy M, et al. for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892-903.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54:810-9.
de Zeeuw D, Akozawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369:2492-503.
Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGFbeta 1 in patients with type 2 diabetes nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011; 80:851-60.
Fallahzadeh MK, Dormanesh B, Sagheb MM, et al. Effects of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, doubleblind placebo-controlled trial. Am J Kidney Dis 2012; 60:896-903.
De Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014; 25:1083-93.
Shan D, Wu HM, QY Y, et al. Pentoxifylline for diabetic kidney disease. Cochrane Collaboration, 2013, published by John Wiley & Sons, Ltd, issue 4.
Navarro-Gonzalez JF, Mora-Fern?ndez C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial. J Am Soc Nephrol 2015; 26:220-9.
Liu P, Chen Y, Wang B, et al. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol 2014; Epub ahead of print.
